Cargando…

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gobin, Bérengère, Moriceau, Gatien, Ory, Benjamin, Charrier, Céline, Brion, Régis, Blanchard, Frederic, Redini, Françoise, Heymann, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944320/ https://www.ncbi.nlm.nih.gov/pubmed/24599309 http://dx.doi.org/10.1371/journal.pone.0090795

Ejemplares similares

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells
por: Ory, B, et al.
Publicado: (2008)

Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases
por: Lamora, Audrey, et al.
Publicado: (2015)

LIM Kinases in Osteosarcoma Development
por: Brion, Régis, et al.
Publicado: (2021)

Jaw osteosarcoma models in mice: first description
por: Bertin, Hélios, et al.
Publicado: (2019)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

Current Therapeutic Strategies and Novel Approaches in Osteosarcoma
por: Ando, Kosei, et al.
Publicado: (2013)

The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth
por: Morice, Sarah, et al.
Publicado: (2020)

Involvement of the TGF-β Signaling Pathway in the Development of YAP-Driven Osteosarcoma Lung Metastasis
por: Morice, Sarah, et al.
Publicado: (2021)

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma
por: Lamoureux, Francois, et al.
Publicado: (2014)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Imatinib mesylate resistance and mutations: An Indian experience
por: Srivastava, Shweta, et al.
Publicado: (2013)

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

The teratogenic effects of imatinib mesylate on rat fetuses
por: El Gendy, M.M., et al.
Publicado: (2015)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Ageing is a risk factor in imatinib mesylate cardiotoxicity
por: Maharsy, Wael, et al.
Publicado: (2014)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
por: Karolewicz, Bożena, et al.
Publicado: (2019)

Molecular Alterations Associated with Osteosarcoma Development
por: Ando, Kosei, et al.
Publicado: (2012)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

ICG-001, an Inhibitor of the β-Catenin and cAMP Response Element-Binding Protein Dependent Gene Transcription, Decreases Proliferation but Enhances Migration of Osteosarcoma Cells
por: Danieau, Geoffroy, et al.
Publicado: (2021)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619
por: Lavaud, Mélanie, et al.
Publicado: (2021)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Generalized Lichenoid Drug Eruption Associated with Imatinib Mesylate Therapy
por: Ghosh, Sudip Kumar
Publicado: (2013)

A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
por: Le Goff, Benoit, et al.
Publicado: (2009)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
por: Cho, Ah Young, et al.
Publicado: (2011)

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells
por: Weigel, Marion T, et al.
Publicado: (2010)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Imatinib Mesylate-Induced Cutaneous Rash Masquerading as Pityriasis Rosea of Gilbert
por: Verma, Prashant, et al.
Publicado: (2014)

Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor
por: Quezada, Nicolás, et al.
Publicado: (2014)

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
por: Lee, Jae-Hyung, et al.
Publicado: (2013)

Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model
por: Suzuki, Naomi, et al.
Publicado: (2013)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i8ps344ppl88p6uakhu26gr6sj